Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Once-monthly injectable medication for alcohol dependence now available in United States
July 14th, 2006
Cephalon, Inc. (CEPH) and Alkermes, Inc. (ALKS) announced that Vivitrol (naltrexone for extended-release injectable suspension), a once-monthly injectable medication for alcohol dependence, is now commercially available in the United States. Vivitrol is indicated for patients who are able to abstain from drinking in an outpatient setting and are not actively drinking when initiating treatment. Vivitrol should be used as part of a comprehensive treatment management program, which includes psychosocial support, such as counseling or group therapy. The U.S. Food and Drug Administration (FDA) approved Vivitrol in April 2006. In clinical studies, people...
Source: Genomics & Genetics Weekly (2006-07-14)
|
